Histone-Lysine N-Methyltransferase
"Histone-Lysine N-Methyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the methylation of the epsilon-amino group of lysine residues in proteins to yield epsilon mono-, di-, and trimethyllysine. EC 2.1.1.43.
Descriptor ID |
D011495
|
MeSH Number(s) |
D08.811.913.555.500.800.400
|
Concept/Terms |
Histone-Lysine N-Methyltransferase- Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase
- N-Methyltransferase, Histone-Lysine
- Protein Methylase III
- Histone-Lysine Methyltransferase
- Histone Lysine Methyltransferase
- Methyltransferase, Histone-Lysine
- Protein Lysine Methyltransferase
- Methyltransferase, Protein Lysine
- Protein Methyltransferase III
|
Below are MeSH descriptors whose meaning is more general than "Histone-Lysine N-Methyltransferase".
Below are MeSH descriptors whose meaning is more specific than "Histone-Lysine N-Methyltransferase".
This graph shows the total number of publications written about "Histone-Lysine N-Methyltransferase" by people in this website by year, and whether "Histone-Lysine N-Methyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 1 | 1 |
2001 | 1 | 1 | 2 |
2004 | 0 | 2 | 2 |
2005 | 0 | 9 | 9 |
2006 | 2 | 2 | 4 |
2007 | 4 | 4 | 8 |
2008 | 4 | 7 | 11 |
2009 | 3 | 6 | 9 |
2010 | 4 | 14 | 18 |
2011 | 4 | 6 | 10 |
2012 | 4 | 10 | 14 |
2013 | 2 | 9 | 11 |
2014 | 7 | 13 | 20 |
2015 | 3 | 6 | 9 |
2016 | 10 | 9 | 19 |
2017 | 3 | 3 | 6 |
2018 | 9 | 4 | 13 |
2019 | 6 | 3 | 9 |
2020 | 7 | 3 | 10 |
2021 | 10 | 2 | 12 |
2022 | 1 | 5 | 6 |
2023 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone-Lysine N-Methyltransferase" by people in Profiles.
-
Rare de novo gain-of-function missense variants in DOT1L are associated with developmental delay and congenital anomalies. Am J Hum Genet. 2023 11 02; 110(11):1919-1937.
-
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023 04 13; 13(1):53.
-
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924.
-
A clustering of heterozygous missense variants in the crucial chromatin modifier WDR5 defines a new neurodevelopmental disorder. HGG Adv. 2023 01 12; 4(1):100157.
-
DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-?B-HIF1a axis. FEBS J. 2023 01; 290(2):502-520.
-
Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife. 2022 08 31; 11.
-
EZH2 Inhibitors: The Unpacking Revolution. Cancer Res. 2022 02 01; 82(3):359-361.
-
Methyl-lysine readers PHF20 and PHF20L1 define two distinct?gene expression-regulating NSL complexes. J Biol Chem. 2022 03; 298(3):101588.
-
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5.
-
Postnatal expression of the lysine methyltransferase SETD1B is essential for learning and the regulation of neuron-enriched genes. EMBO J. 2022 01 04; 41(1):e106459.